Claims
- 1. A pharmaceutical composition comprising 7,7′-(carbonyl-bis(imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-pyrrole)carbonylimino))bis(1,3-naphthalen-disulfonic acid) tetrasodium salt, and an antineoplastic agent selected from the group consisting of paclitaxel, cisplatin, etoposide, irinotecan, and 9-aminocamptothecin, in amounts effective to produce a synergistic antineoplastic effect.
- 2. A pharmaceutical composition according to claim 1, wherein the antineoplastic agent is paclitaxel.
- 3. A pharmaceutical composition according to claim 1, wherein the antineoplastic agent is cisplatin.
- 4. A pharmaceutical composition according to claim 1, wherein the antineoplastic agent is etoposide.
- 5. A pharmaceutical composition according to claim 1, wherein the antineoplastic agent is irinotecan.
- 6. A pharmaceutical composition according to claim 1, wherein the antineoplastic agent is 9-aminocamptothecin.
- 7. A method of treating a mammal, suffering from a neoplastic disease state selected from the group consisting of leukemia, carcinoma, lymphoma and osteosarcoma, comprising administering to said mammal a biologically active ureido compound of formula (I) whereineach of m and n, being the same, is an integer of 1 to 3; and each of the R groups, which are the same, is a naphthyl group substituted by 1 to 3 sulfonic groups, or a pharmaceutically acceptable salt thereof, and vinblastin in amounts effective to produce a synergistic antineoplastic effect.
- 8. A method of treating a mammal, suffering from a neoplastic disease state selected from the group consisting of carcinoma, testicular teratoma and ovarian carcinoma, comprising administering to said mammal a biologically active ureido compound of formula (I) whereineach of m and n, being the same, is an integer of 1 to 3; and each of the R groups, which are the same, is a naphthyl group substituted by 1 to 3 sulfonic groups, or a pharmaceutically acceptable salt thereof, and cisplatin in amounts effective to produce a synergistic antineoplastic effect.
- 9. A method of treating a mammal, suffering from a neoplastic disease state selected from the group consisting of breast carcinoma, leukemia, lymphoma and ovarian carcinoma, comprising administering to said mammal a biologically active ureido compound of formula (I) whereineach of m and n, being the same, is an integer of 1 to 3; and each of the R groups, which are the same, is a naphthyl group substituted by 1 to 3 sulfonic groups, or a pharmaceutically acceptable salt thereof, and epirubicin in amounts effective to produce a synergistic antineoplastic effect.
- 10. A method of treating a mammal, suffering from a neoplastic disease state consisting of leukemia, comprising administering to said mammal a biologically active ureido compound of formula (I) whereineach of m and n, being the same, is an integer of 1 to 3; and each of the R groups, which are the same, is a naphthyl group substituted by 1 to 3 sulfonic groups, or a pharmaceutically acceptable salt thereof, and cytarabine in amounts effective to produce a synergistic antineoplastic effect.
- 11. A method of treating a mammal, suffering from a neoplastic disease state selected from the group consisting of advanced colon and ovarian cancer comprising administering to said mammal a biologically active ureido compound of formula (I) whereineach of m and n, being the same, is an integer of 1 to 3; and each of the R groups, which are the same, is a naphthyl group substituted by 1 to 3 sulfonic groups, or a pharmaceutically acceptable salt thereof, and CPT-11 or 9-aminocamptothecin in amounts effective to produce a synergistic antineoplastic effect.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9727524 |
Dec 1997 |
GB |
|
Parent Case Info
This application is a 371 of PCT/EP98/08159 filed on Dec. 12, 1998.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/EP98/08159 |
|
WO |
00 |
8/30/1999 |
8/30/1999 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO99/34796 |
7/15/1999 |
WO |
A |
US Referenced Citations (5)
Number |
Name |
Date |
Kind |
5260329 |
Mongelli et al. |
Nov 1993 |
|
5420296 |
Mongelli et al. |
May 1995 |
|
5534539 |
Mongelli et al. |
Jul 1996 |
|
5593976 |
Mongelli et al. |
Jan 1997 |
|
5859046 |
Alzani et al. |
Jan 1999 |
|